Hans Bishop, Jennifer Cook, Joshua Ofman, Maykin Ho, Renée Galá
Grail has appointed Hans Bishop as the firm's CEO. He succeeds Jennifer Cook, who has stepped down from the position for family health reasons. Bishop has served on the firm's board of directors since 2018 and will continue serving as its director. Bishop will also continue serving as executive chair of the Sana board of directors, as well as director of Celgene, Agilent Technologies, and Lyell Immunopharma. Bishop founded Juno Therapeutics in 2013 and served as the firm's president and CEO until it was acquired by Celgene in 2018. Prior to Juno, he served as executive in residence at Warburg Pincus. Before Warburg, Bishop served as executive VP and chief operating officer for Dendreon. Prior to Dendreon, he served as president of specialty medicine at Bayer Healthcare, senior VP of global commercial operations at Chiron, and VP and general manager of European Biopharmaceuticals.
Grail has also appointed Joshua Ofman as its chief of corporate strategy and external affairs. Prior to Grail, Ofman most recently served as senior VP of global health policy at Amgen. Before joining Amgen in 2003, Ofman was a member of the academic faculty at the University of California, Los Angeles School of Medicine, Cedars-Sinai Medicine Center. Ofman also served as senior VP of Zynx Health.
Grail has also appointed Maykin Ho to its board as an independent director. Ho is currently a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. She serves on the board of directors for FibroGen, Agios Pharmaceuticals, Parexel International, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. Ho is a retired partner of the Goldman Sachs Group, where she served as senior biotechnology analyst, co-head of healthcare for global investment research, and advisory director for healthcare investment banking. Before Goldman Sachs, Ho held various managerial positions at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company.
Grail also announced that Renée Galá has stepped down as the firm's CFO.
Andrew Quong
Andrew Quong has joined Fluidigm as the company's first-ever CSO. Quong was most recently director of strategic scientific initiatives and partnerships at the Frederick National Laboratory for Cancer Research, a National Cancer Institute-sponsored center. Prior to this, Quong served as a faculty member in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University.
Ronald Andrews
OncoCyte has appointed Ronald Andrews as its CEO, effective July 1. In addition to serving as a board member at OncoCyte, Andrews has over 30 years of experience in the clinical and molecular diagnostics field. OncoCyte's current CEO, William Annett, will remain with the company in an advisory role.
Prior to joining the firm, Andrews was the founder and principal of the Bethesda Group. Before Bethesda, he served as Thermo Fisher Scientific's genetic science division president, where he oversaw the integration of Life Technologies' genetic platform. He also served as president of Life Tech's Medical Science Venture. Before joining Life Tech, Andrews acted as CEO at Clarient (formerly ChromaVision Medical Systems), which was sold to GE Healthcare in 2010. He subsequently served as GE Molecular Diagnostics' CEO until 2011. Andrews also held various senior executive roles at Roche Diagnostics from 2000 to 2004. Andrews served as VP of marketing at Immucor from 1995 to 2000. Prior to Immucor, Andrews spent about 10 years in management positions at Abbott Diagnostics.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.